Recanaclotide - Ironwood Pharmaceuticals

Drug Profile

Recanaclotide - Ironwood Pharmaceuticals

Alternative Names: IW-9179

Latest Information Update: 12 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ironwood Pharmaceuticals
  • Class Antiulcers; Gastrokinetics; Peptides
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyspepsia
  • Discontinued Diabetic gastroparesis

Most Recent Events

  • 05 Apr 2016 Discontinued - Phase-II for Diabetic gastroparesis in USA (PO)
  • 05 Apr 2016 Top-line adverse events data from a phase IIa trial in Diabetic gastroparesis released by Ironwood Pharmaceuticals
  • 17 Aug 2015 Phase-II development for Functional dyspepsia is ongoing in Belgium and Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top